Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amedisys inc. - AMED

AMED

Close Chg Chg %
85.60 0.08 0.09%

Closed Market

85.68

+0.08 (0.09%)

Volume: 388.02K

Last Updated:

Dec 13, 2024, 4:00 PM EDT

Trade Now

Company Overview: amedisys inc. - AMED

AMED Key Data

Open

$85.63

 Day Range

85.38 - 85.93

52 Week Range

84.10 - 98.95

 Market Cap

$2.80B

Shares Outstanding

32.75M

 Public Float

32.03M

Beta

0.73

 Rev. Per Employee

N/A

P/E Ratio

34.08

 EPS

$2.54

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

536.54K

  

AMED Performance

1 Week
 
 -0.41%
 
1 Month
 
 -4.85%
 
3 Months
 
 -11.59%
 
1 Year
 
 -9.38%
 
5 Years
 
 -47.21%
 

AMED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About amedisys inc. - AMED

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

AMED At a Glance

Amedisys, Inc.
3854 American Way
Baton Rouge, Louisiana 70816
Phone 1-225-292-2031 Revenue 2.24B
Industry Medical/Nursing Services Net Income -9,747,000.00
Sector Health Services 2023 Sales Growth 0.593%
Fiscal Year-end 12 / 2024 Employees 19,000
View SEC Filings

AMED Valuation

P/E Current 34.083
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.386
Price to Book Ratio 2.912
Price to Cash Flow Ratio 22.588
Enterprise Value to EBITDA 16.105
Enterprise Value to Sales 1.562
Total Debt to Enterprise Value 0.139

AMED Efficiency

Revenue/Employee 117,704.316
Income Per Employee -513.00
Receivables Turnover 6.815
Total Asset Turnover 1.108

AMED Liquidity

Current Ratio 1.049
Quick Ratio 1.049
Cash Ratio 0.308

AMED Profitability

Gross Margin 20.438
Operating Margin 8.633
Pretax Margin 1.772
Net Margin -0.436
Return on Assets -0.483
Return on Equity -0.92
Return on Total Capital -0.627
Return on Invested Capital -0.643

AMED Capital Structure

Total Debt to Total Equity 45.683
Total Debt to Total Capital 31.358
Total Debt to Total Assets 23.649
Long-Term Debt to Equity 39.813
Long-Term Debt to Total Capital 27.329
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amedisys Inc. - AMED

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
2.07B 2.21B 2.22B 2.24B
Sales Growth
+5.93% +6.88% +0.41% +0.59%
Cost of Goods Sold (COGS) incl D&A
1.21B 1.26B 1.29B 1.78B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
28.80M 30.90M 24.93M 23.85M
Depreciation
12.10M 12.10M 11.50M 18.20M
Amortization of Intangibles
16.70M 18.80M 13.44M 5.65M
COGS Growth
+3.88% +4.13% +1.67% +38.43%
Gross Income
857.35M 949.86M 937.84M 457.08M
Gross Income Growth
+8.96% +10.79% -1.27% -51.26%
Gross Profit Margin
+41.39% +42.90% +42.18% +20.44%
2020 2021 2022 2023 5-year trend
SG&A Expense
658.20M 703.58M 754.06M 26.08M
Research & Development
- - - -
-
Other SG&A
658.20M 703.58M 754.06M 26.08M
SGA Growth
+11.08% +6.89% +7.17% -96.54%
Other Operating Expense
- - - 237.93M
-
Unusual Expense
14.25M 7.66M 3.01M 142.67M
EBIT after Unusual Expense
184.90M 238.62M 180.77M 50.39M
Non Operating Income/Expense
36.96M 51.14M 1.70M 20.50M
Non-Operating Interest Income
292.00K 49.00K 178.00K 3.27M
Equity in Earnings of Affiliates
3.97M 4.95M (45.00K) 10.76M
Interest Expense
11.04M 9.53M 22.23M 31.27M
Interest Expense Growth
-23.95% -13.71% +133.36% +40.70%
Gross Interest Expense
11.04M 9.53M 22.23M 31.27M
Interest Capitalized
- - - -
-
Pretax Income
210.82M 280.23M 160.24M 39.62M
Pretax Income Growth
+23.71% +32.92% -42.82% -75.27%
Pretax Margin
+10.18% +12.66% +7.21% +1.77%
Income Tax
25.64M 70.06M 42.55M 50.56M
Income Tax - Current - Domestic
52.20M 25.48M 19.17M 29.90M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(26.56M) 44.58M 23.38M 20.66M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
3.97M 4.95M (45.00K) 10.76M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
185.18M 210.17M 117.70M (10.94M)
Minority Interest Expense
1.58M 1.09M (910.00K) (1.19M)
Net Income
183.61M 209.07M 118.61M (9.75M)
Net Income Growth
+44.76% +13.87% -43.27% -108.22%
Net Margin Growth
+8.86% +9.44% +5.34% -0.44%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
183.61M 209.07M 118.61M (9.75M)
Preferred Dividends
- - - -
-
Net Income Available to Common
183.61M 209.07M 118.61M (9.75M)
EPS (Basic)
5.6392 6.405 3.6476 -0.299
EPS (Basic) Growth
+42.91% +13.58% -43.05% -108.20%
Basic Shares Outstanding
32.56M 32.64M 32.52M 32.60M
EPS (Diluted)
5.5191 6.3409 3.6324 -0.299
EPS (Diluted) Growth
+43.55% +14.89% -42.71% -108.23%
Diluted Shares Outstanding
33.27M 32.97M 32.65M 32.60M
EBITDA
227.95M 277.18M 208.72M 216.91M
EBITDA Growth
+7.13% +21.59% -24.70% +3.93%
EBITDA Margin
+11.00% +12.52% +9.39% +9.70%

Snapshot

Average Recommendation HOLD Average Target Price 101.00
Number of Ratings 8 Current Quarters Estimate 1.063
FY Report Date 12 / 2024 Current Year's Estimate 4.39
Last Quarter’s Earnings 1.00 Median PE on CY Estimate N/A
Year Ago Earnings 4.30 Next Fiscal Year Estimate 4.919
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 6 10 9
Mean Estimate 1.06 1.11 4.39 4.92
High Estimates 1.14 1.18 4.55 5.20
Low Estimate 0.95 1.05 4.12 4.68
Coefficient of Variance 4.76 4.08 2.61 3.45

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 8 8 8
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Amedisys Inc. - AMED

Date Name Shares Transaction Value
Nov 8, 2024 Nick Muscato Chief Strategy Officer 30,829 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Allyson Guidroz Chief Accounting Officer 6,819 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $91.15 per share 621,551.85
May 8, 2024 Molly Joel Coye Director 7,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Allyson Guidroz Chief Accounting Officer 6,994 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.08 per share 644,007.52
May 8, 2024 Ivanetta Davis Samuels Director 5,910 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Jeffrey A. Rideout Director 7,645 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Julie D. Klapstein Director 14,341 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Paul B. K. Kusserow Director 353,670 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Teresa L. Kline Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Vickie L. Capps Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Bruce Devereau Perkins Director 22,407 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Scott G. Ginn EVP, CFO & COO 83,177 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $93.69 per share 7,792,853.13
Feb 22, 2024 Scott G. Ginn EVP, CFO & COO 86,395 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Nick Muscato Chief Strategy Officer 20,516 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $93.69 per share 1,922,144.04
Feb 22, 2024 Richard M. Ashworth President and CEO; Director 112,688 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Adam Holton Chief People Officer 10,863 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Michael P. North Chief Information Officer 23,932 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Michael P. North Chief Information Officer 22,341 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $93.69 per share 2,093,128.29
Feb 22, 2024 Denise M. Bohnert Chief Compliance Officer 17,258 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 22, 2024 Denise M. Bohnert Chief Compliance Officer 15,843 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $93.69 per share 1,484,330.67

Amedisys Inc. in the News